13476-55-6

Basic information

• Product Name: 4-AMINO-BENZOIC ACID HEXYL ESTER
• Synonyms: AURORA 4261;4-AMINO-BENZOIC ACID HEXYL ESTER;OTAVA-BB BB0109160018;Benzoic acid, 4-aMino-, hexyl ester;hexyl 4-aminobenzoate
• CAS NO: 13476-55-6
• Molecular Formula: C₁₃H₁₉NO₂
• Molecular Weight: 221.3
• Mol File: 13476-55-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 60.5-61.5 °C
• Boiling Point: 363.5°C at 760 mmHg
• Flash Point: 205.6°C
• Appearance: /
• Density: 1.043g/cm³
• Vapor Pressure: 1.8E-05mmHg at 25°C
• Refractive Index: 1.528
• PKA: 2.42±0.10(Predicted)
• CAS DataBase Reference: 4-AMINO-BENZOIC ACID HEXYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-BENZOIC ACID HEXYL ESTER(13476-55-6)
• EPA Substance Registry System: 4-AMINO-BENZOIC ACID HEXYL ESTER(13476-55-6)

Safety Data

• Hazardous Substances Data: 13476-55-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H19NO2/c1-2-3-4-5-10-16-13(15)11-6-8-12(14)9-7-11/h6-9H,2-5,10,14H2,1H3

Upstream product

• 6268-24-2 n-hexyl p-nitrobenzoate 
• 150-13-0 4-amino-benzoic acid 
• 111-27-3 hexan-1-ol 
• 6835-50-3 hex-5-enyl 4-nitrobenzoate 
• 869657-87-4 6-bromohexyl 4-nitrobenzoate 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 1246881-86-6 hexyl 4-amino-3-bromobenzoate 
• 299965-41-6 4-(4-(hexyloxycarbonyl)phenylamino)-3,5-dinitrobenzoic acid 
• 1610566-94-3 methyl 3-(4-(hexyloxycarbonyl)phenylamino)-5-nitrobenzoate 

Relevant articles and documents

Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: The 14-3-3σ case

Targeting the binding site of 14-3-3 proteins lets the release of partner proteins involved in cell cycle progression, apoptosis, cytoskeletal rearrangement and transcriptional regulation and may therefore be regarded as an alternative strategy to integra

Discovery of 14-3-3 protein-protein interaction inhibitors that sensitize multidrug-resistant cancer cells to doxorubicin and the Akt inhibitor GSK690693

14-3-3 is a family of highly conserved adapter proteins that is attracting much interest among medicinal chemists. Small-molecule inhibitors of 14-3-3 protein-protein interactions (PPIs) are in high demand, both as tools to increase our understanding of 14-3-3 actions in human diseases and as leads to develop innovative therapeutic agents. Herein we present the discovery of novel 14-3-3 PPI inhibitors through a multidisciplinary strategy combining molecular modeling, organic synthesis, image-based high-content analysis of reporter cells, and in vitro assays using cancer cells. Notably, the two most active compounds promoted the translocation of c-Abl and FOXO pro-apoptotic factors into the nucleus and sensitized multidrug-resistant cancer cells to apoptotic inducers such as doxorubicin and the pan-Akt inhibitor GSK690693, thus becoming valuable lead candidates for further optimization. Our results emphasize the possible role of 14-3-3 PPI inhibitors in anticancer combination therapies. Pièce de résistance! Multidrug resistance (MDR) is the main obstacle toward effective anticancer therapy. Herein we report the discovery of two small-molecule 14-3-3 protein-protein interaction inhibitors that promote the translocation of c-Abl and FOXO pro-apoptotic factors into the nucleus and sensitize MDR cancer cells to doxorubicin and the pan-Akt inhibitor GSK690693.

Synthesis of symmetric diester-functionalised Troeger's base analogues

The yields of ester-functionalised Troeger's base analogues are dramatically improved by incorporating an electron-donating group on the aromatic ring and/or enhancing solubil- ity of the aniline unit. In addition to 2,8-diester compounds, 1,7-, 3,9- and 4,10-diester-functionalised Troeger's base analogues have been prepared for the first time.